6-氯咪唑并[1,2-a]吡啶-3-甲酸 | 138642-97-4

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-氯咪唑并[1,2-a]吡啶-3-甲酸
• 英文名称: 6-Chloroimidazo[1,2-a]pyridine-3-carboxylic acid
• CAS: 138642-97-4
• 化学式: C₈H₅ClN₂O₂
• mdl: MFCD07021509
• 分子量: 196.59
• InChiKey: LXRDUEDQFSBROM-UHFFFAOYSA-N

物化性质

• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE KINASES IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021158634A1

  公开（公告）日：2021-08-12

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。
• IRAK DEGRADERS AND USES THEREOF
  申请人：Kymera Therapeutics, Inc.

  公开号：EP4100004A1

  公开（公告）日：2022-12-14
• Heterocyclic Compounds and Uses Thereof
  申请人：Intellikine LLC

  公开号：US20180042902A1

  公开（公告）日：2018-02-15

  Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
• Krüppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney Disease
  申请人：United States Government as represented by the Department of Veterans Affairs

  公开号：US20210347734A1

  公开（公告）日：2021-11-11

  The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• [EN] KRÜPPEL-LIKE FACTOR 15 (KLF15) SMALL MOLECULE AGONISTS IN KIDNEY DISEASE<br/>[FR] AGONISTES DE PETITES MOLÉCULES DU FACTEUR 15 DE TYPE KRÜPPEL (KLF15) DANS UNE MALADIE RÉNALE
  申请人：US GOV VETERANS AFFAIRS

  公开号：WO2021222637A1

  公开（公告）日：2021-11-04

  The present disclosure is concerned with small molecule modulators of KLF15 signaling useful for treating various disorders such as, for example, kidney disease (e.g., chronic kidney disease), heart disease, obesity, or a neurodegenerative disorder (e.g., amyotrophic lateral sclerosis (ALS), Alzheimer´s disease, Parkinson´s disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington´s disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.